Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody|cas:1447814-75-6|西域试剂

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody

产品编号：Bellancom-P99258| CAS NO：1447814-75-6

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99258		￥4500.00	杭州北京（现货）
Bellancom-P99258		￥11700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody

产品介绍

Brontictuzumab (OMP 52M51) 是一种单克隆抗体 (MAb)，可抑制 Notch1 信号。Brontictuzumab 选择性结合 Notch1 的负调控区域。Brontictuzumab 可抑制肿瘤细胞增殖。Brontictuzumab 可用于白血病和淋巴瘤的研究。

生物活性

Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.

体外研究

Brontictuzumab (0-100 μg/mL) inhibits Notch1 signaling, including DLL4, JAG1/2 activity.
Brontictuzumab (25 μg/mL, 4 days) reduces the levels of Notch1 intracellular domain in the HPB-ALL cell line.
Brontictuzumab (25 μg/mL, 48 h) inhibits DLL4-mediated cleaved-Notch1 overexpression in MCL cells.
Brontictuzumab (25 μg/mL, 48 h) blocks the increased phosphorylation of both, MEK and ERK by DLL4 stimulation in Mino cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	DLL4 (4 μg/mL)-stimulated MCL cells
Concentration:	25 μg/mL
Incubation Time:	24 or 48 h
Result:	Inhibited DLL4-dependent activation of Notch1.

体内研究
(In Vivo)

Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft.
Brontictuzumab (20 mg/kg, i.p., every 4 days) inhibits DLL4 induced activation of Notch1 in MCL model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	T-ALL xenograft
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection (i.p.), twice weekly.
Result:	Inhibited tumor growth and reduced the size of the spleen. Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.

Animal Model:	NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.

体内研究

Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft.
Brontictuzumab (20 mg/kg, i.p., every 4 days) inhibits DLL4 induced activation of Notch1 in MCL model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	T-ALL xenograft
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection (i.p.), twice weekly.
Result:	Inhibited tumor growth and reduced the size of the spleen. Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.

Animal Model:	NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.

体内研究

Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft.
Brontictuzumab (20 mg/kg, i.p., every 4 days) inhibits DLL4 induced activation of Notch1 in MCL model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	T-ALL xenograft
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection (i.p.), twice weekly.
Result:	Inhibited tumor growth and reduced the size of the spleen. Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.

Animal Model:	NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.